

Cancer Cell

Greeting from the new Editor

The interaction between basic and clinical cancer researchers has become closer in recent years, which has accelerated the progress in diagnosis, treatment, and prevention of cancer. However, there is clearly still room to improve the dialog between the basic and clinical cancer research communities. *Cancer Cell* was launched in February 2002 with the goal of creating a high-profile forum for showcasing advances in cancer research. For me, as an active cancer researcher at that time, the launch of *Cancer Cell* was very exciting news.

In the short period of time since its first issue, *Cancer Cell* has become a leading journal in cancer research. The success of the journal rests on the support of the cancer research community and a strong editorial commitment and vision. I therefore consider it a great privilege and an exciting challenge to take on the editorial leadership of *Cancer Cell* and would like to take this opportunity to introduce myself. I received my Ph.D. from the University of Pennsylvania for study on the function of the murine immunoglobulin heavy chain gene enhancer. From there, I pursued postdoctoral training at Cold Spring Harbor Laboratory, where my work was focused on the retinoblastoma gene family and cell cycle regulation. I continued my training at Johns Hopkins Oncology Center during which time I participated in the cloning of the Adenomatous Polyposis Coli (*APC*) tumor suppressor gene and further studied its function. In 1995, I joined the faculty at the University of Texas M. D. Anderson Cancer Center and built a research program focused on the genetics and function of the *APC* and *BRCA2* tumor suppressor genes and the human EB1 family proteins. From working at M. D. Anderson Cancer Center, which is one of the largest cancer centers in the world and has for many years emphasized translational research and fostered an environment for collaboration between basic and clinical researchers, I came to appreciate first-hand the importance of close interactions between these two communities for progress in cancer research. My experiences as a researcher, author, and reviewer have made me realize the value of good editorial judgment and will serve me well in my interactions with the community.

I am very pleased to have Anita Ballesteros as an Assistant Editor on the *Cancer Cell* team; she joined the journal in June 2002 and her experience is a valuable asset. Anita holds a doctorate in molecular oncology from New York University, where her research focused on tumor suppressor genes. Her postdoctoral research in cell cycle and apoptosis was conducted at the University of Massachusetts Medical School. Anita's broad scientific interests and commitment have played a critical role in building the journal. Many of you may have already had the opportunity to interact with Anita and experience her enthusiasm. Judith Glaven has been a Consulting Editor on *Cancer Cell* since the launch of the journal. Judy's background is in signaling and the regulation of cell proliferation, and she has been on the editorial team of *Cell*, *Molecular Cell*, and *Developmental Cell* for many years. Judy's research and editorial experience is a tremendous asset for *Cancer Cell*. I am very delighted that Charles Sawyers and William Sellers have agreed to join the *Cancer Cell* team as Reviews Editors and look forward to publishing a range of high-quality review material.

The mission of *Cancer Cell* continues to be serving the cancer research community by publishing exciting and highly significant works in a broad range of cancer research from basic molecular and cellular biology of cancer to clinical oncology. Areas within the scope of *Cancer Cell* include the elucidation of molecular and cellular mechanisms of fundamental cancer biology such as apoptosis, cell cycle/checkpoint regulation, and genetic and epigenetic regulation of genes important for tumorigenesis, angiogenesis, invasion, and metastasis; the use of genomic and/or proteomic approaches to better classify cancers and to understand the response of cells to various treatments; the application of technologies in structural biology and large-scale functional screening of small molecules for the design and identification of potentially useful biological target-directed drugs; development and elucidation of mechanisms for novel biological therapeutics; the development and analysis of sophisticated animal models mimicking human tumor development that allow more accurate preclinical

testing of diagnosis, treatment, and prevention strategies; and application of principles of basic tumor biology toward novel strategies for cancer prevention. The primary criterion for publication in *Cancer Cell* is that the work must provide new biological insight into important questions relevant to human cancer and be of exceptional significance to the field.

Cancer Cell is continuing to improve our service to our contributors and readers. The journal has implemented an online submission and review program to expedite the review process. As a service to authors, *Cancer Cell* writes and distributes a press release promoting the work in each issue to a large list of press contacts. To serve our readers better, the journal will publish an online annotated table of contents, and I invite all our readers to register to receive the monthly electronic table of contents by e-mail.

The strong support from Cell Press, both strategically and operationally, has contributed significantly to the success of *Cancer Cell*. The experienced and talented acting editorial team, which includes Judith Glaven, Lakshmi Goyal, Emilie Marcus, and Dorit Zuk, has been critical in maintaining the successful growth of *Cancer Cell* in the last few months. The most important factor for the current and future success of this journal is the support from the cancer research community. I thank all of the authors who have published their best work in *Cancer Cell* in the past and would like to invite all cancer researchers working at the bench and/or at the bedside to contribute your most exciting and significant work in the future. I thank all the reviewers who have provided constructive, fair, and expedited reviews to ensure the high quality of *Cancer Cell*, and I look forward to the continued support and dedication of our reviewers. Last but not least, the encouragement and support of the Editorial Board have played a tremendous role in the success of *Cancer Cell*. I sincerely thank all the board members.

It is an exciting time in cancer research. I look forward to working with you on the continued development of *Cancer Cell* and toward the common goal of understanding cancer and contributing to the important fight against this complex disease.

Li-Kuo Su